R.PR
REGISTERED-PRINCIPAL REGISTER
07/14/2020
Back to search
Official data from USPTO
NANOGENICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
NANOGENICS
ST13
US500000088072409Class
5, 42
Filing
88072409
Registration
6098589
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
07/14/2020
Trademark type
Word
Nice classes
5, 42
Filing date
08/09/2018
Registration date
07/14/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/14/2020
Last transaction
07/14/2020
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
99
Owner location
London, GB
Examiner
COLLOPY, DIANE PATRICIA
Law office
L70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Nanogenics Limited
Representatives
Thomas W. Cole ROBERTS MLOTKOWSKI SAFRAN COLE & CALDERON P.C.
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and natural remedies for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderscystic fibrosisglaucomaeye diseasesbone diseasesvascular diseasesliver diseasesimmune system-related diseases and disordersdiseases of the brain; medical preparations for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseasesimmune system-related diseases and disordersdiseases of the brain; medical preparations being pharmaceuticals for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseasesimmune system-related diseases and disordersdiseases of the brain; medical preparations being nanoparticles for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseaseimmune system-related diseases and disordersdiseases of the brain; medical preparations containing siRNARNAshRNAmRNA or DNA for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseasesimmune system-related diseases and disordersdiseases of the brain; pharmaceutical medical preparations being nanoparticles for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseaseimmune system-related diseases and disordersdiseases of the brain; medical preparations being pharmaceuticals containing siRNA for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseaseimmune system-related diseases and disordersdiseases of the brain; medical preparations being pharmaceuticals containing shRNA for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseaseimmune system-related diseases and disordersdiseases of the brain; medical preparations being pharmaceuticals containing mRNA for treatments in the form of gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseaseimmune system-related diseases and disordersdiseases of the brain; medical preparations being pharmaceuticals containing DNA for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseaseimmune system-related diseases and disordersdiseases of the brain; medical preparations containing lipidsliposomes or peptides for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseaseimmune system-related diseases and disordersdiseases of the brain; medical preparations being pharmaceuticals containing lipidsliposomes or peptides for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseaseimmune system-related diseases and disordersdiseases of the brain; medical preparations for use in gene therapy for the treatment of tumours; biochemical preparations for medical purposes for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseaseimmune system-related diseases and disordersdiseases of the brain; biological preparations for medical purposes for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseaseimmune system-related diseases and disordersdiseases of the brain; reagents for medical use; reagents for use in medical genetic testing; anti-cancer preparations; anti-cancer drugs; compounds for treating cancer; biopharmaceuticals for the treatment of cancer; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-cancer preparations of microbial origin; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations being nanoparticles for the treatment of cancer; pharmaceutical preparations containing siRNARNAshRNAmRNA or DNA for the treatment of cancer; pharmaceutical products for the treatment of cancer; biological preparations for the treatment of cancer; anti-cancer preparations from hormones and antagonists; pharmaceutical preparations and substances for the prevention of cancer; chemotherapeutics for use in the treatment of cancer; pharmaceutical preparations for use in chemotherapy for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment and prevention of tumours; drug delivery agents in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals ; drug delivery agents being made from lipidsliposomes or peptides in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; drug delivery agents that facilitate the delivery of pharmaceutical preparations in the form of nanoparticles; drug delivery agents for use in relation to the delivery of siRNAshRNAmRNARNADNA or other genetic material in the form of nanoparticles; drug delivery agents for use in gene therapy in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; drug delivery agents being nanoparticles in the form of an artificial virus that facilitate the delivery of a wide variety of pharmaceuticals; intravenous fluids used for rehydrationnutrition and the delivery of pharmaceutical preparations; none of the aforesaid for use in relation to the treatment of hair loss or hair growth stimulation
Class 42
Medical and pharmacological research services all in the field of gene therapy and treatment of cancer; biological researchclinical research and medical research all in the field of gene therapy; research in the field of gene therapy; scientific research for medical purposes in the area of cancerous diseases; pharmaceutical product development; research of pharmaceuticals; research relating to pharmaceutical delivery agents; development of pharmaceutical delivery agents; research and development in the pharmaceutical and biotechnology fields; providing information about the results of clinical trials for pharmaceutical products; scientific research services for assessing the efficiency of pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; development of pharmaceutical preparations and substances; development of pharmaceuticals and pharmaceutical preparations being nanoparticles; development of pharmaceuticals and pharmaceutical preparations containing siRNARNAshRNAmRNA or DNA; development of drug delivery agents being made from lipidsliposomes or peptides; development of drug delivery agents that facilitate the delivery of pharmaceuticals and pharmaceutical preparations; development of pharmaceutical and drug delivery agents for use in relation to the delivery of siRNAshRNAmRNARNADNA or other genetic material; development of pharmaceuticals and pharmaceutical preparations for use in gene therapy; development of drug delivery agents for use in gene therapy; development of drug delivery agents being nanoparticles; providing consulting to medical research companies in the design and conduct of clinical trials and proving consulting to pharmaceutical companies in the design of pharmaceutical products
Publications
History of USPTO decisions and trademark events.
29 publications found
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
06/10/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
06/08/2020
IUCN
NOTICE OF ALLOWANCE CANCELLED
04/29/2020
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
04/29/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/28/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/28/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/28/2020
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
04/21/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/25/2020
PUBO
PUBLISHED FOR OPPOSITION
02/25/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/05/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/21/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/28/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/27/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/27/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/30/2019
GNRT
NON-FINAL ACTION E-MAILED
06/30/2019
CNRT
NON-FINAL ACTION WRITTEN
06/30/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/03/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/03/2019
ALIE
ASSIGNED TO LIE
05/30/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/27/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/25/2018
GNRT
NON-FINAL ACTION E-MAILED
11/25/2018
CNRT
NON-FINAL ACTION WRITTEN
11/25/2018
DOCK
ASSIGNED TO EXAMINER
11/15/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/17/2018
NWAP
NEW APPLICATION ENTERED
08/13/2018
Continuous trademark protection
Get notified about every new filing that threatens NANOGENICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.